Skip to main content

Progesterone to Estrogen Ratio Calculator

Free Progesterone estrogen ratio Calculator with medically-sourced formulas. Enter your measurements for personalized, accurate health insights.

Skip to calculator
Medicine & Health

Progesterone to Estrogen Ratio Calculator

Calculate your progesterone to estradiol ratio to assess hormone balance. Evaluate luteal phase adequacy, estrogen dominance, and hormonal health with unit conversions.

Last updated: January 2026Reviewed by NovaCalculator Medical Editorial Team

Calculator

Adjust values & calculate
15 ng/mL
150 pg/mL
Pg/E2 Clinical Ratio
100.0
Normal
The progesterone to estradiol ratio falls within the expected range, suggesting adequate progesterone relative to estrogen levels.
Progesterone
15.00 ng/mL
47.70 nmol/L
Estradiol
150.0 pg/mL
550.6 pmol/L

Phase-Specific Reference Ranges

Follicular PhaseP4: 0.2-1.5 ng/mLE2: 20-150 pg/mLRatio: 10-50
Ovulatory PhaseP4: 1-3 ng/mLE2: 150-400 pg/mLRatio: 5-15
Luteal PhaseP4: 5-20 ng/mLE2: 40-200 pg/mLRatio: 100-500
Pregnancy (1st tri)P4: 10-44 ng/mLE2: 200-6000 pg/mLRatio: 10-100
Medical Disclaimer: This calculator is for educational purposes only. Hormone levels must be interpreted in clinical context including cycle day, symptoms, and medical history. Always consult your healthcare provider for hormone evaluation and treatment decisions.
Your Result
Pg/E2 Ratio: 100.0 | Status: Normal | P4: 15.00 ng/mL | E2: 150.0 pg/mL
Share Your Result
Understand the Math

Formula

Pg/E2 Clinical Ratio = (Progesterone ng/mL / Estradiol pg/mL) x 1000

Where progesterone is measured in ng/mL (or converted from nmol/L by dividing by 3.18) and estradiol is measured in pg/mL (or converted from pmol/L by dividing by 3.671). The multiplication by 1000 normalizes the ratio for clinical interpretation. Optimal luteal phase ratio is typically 100-500.

Last reviewed: January 2026

Worked Examples

Example 1: Mid-Luteal Phase Assessment

A woman has a day 21 blood test showing progesterone of 15 ng/mL and estradiol of 150 pg/mL. Calculate the Pg/E2 ratio and assess luteal phase adequacy.
Solution:
Clinical Ratio = (Progesterone ng/mL / Estradiol pg/mL) x 1000 Clinical Ratio = (15 / 150) x 1000 = 100 Same-unit ratio (both in pg/mL): 15,000 / 150 = 100:1 Luteal phase optimal range: 100-500 Progesterone >10 ng/mL confirms ovulation Result: Ratio of 100 is at the lower end of normal luteal range
Result: Pg/E2 Ratio: 100 - Normal range, confirms ovulation with adequate luteal progesterone

Example 2: Suspected Estrogen Dominance

A woman with PMS symptoms has progesterone of 4 ng/mL and estradiol of 180 pg/mL on day 21. Evaluate the ratio.
Solution:
Clinical Ratio = (4 / 180) x 1000 = 22.2 Same-unit ratio: 4,000 / 180 = 22.2:1 Luteal phase optimal range: 100-500 Ratio of 22.2 is well below the optimal range Progesterone of 4 ng/mL is below the 10 ng/mL threshold for confirmed ovulation This suggests possible anovulation or luteal phase defect
Result: Pg/E2 Ratio: 22.2 - Estrogen Dominant. Low progesterone suggests anovulatory cycle or luteal phase deficiency
Expert Insights

Background & Theory

The Progesterone to Estrogen Ratio Calculator applies the following established principles and formulas. Health and medicine calculators are grounded in validated physiological measurement methods established through decades of clinical research. Body Mass Index, or BMI, is calculated by dividing weight in kilograms by height in meters squared (kg/mยฒ), a formula originating from Adolphe Quetelet's 19th-century statistical work and later codified by the WHO into standard classifications: underweight below 18.5, normal weight 18.5 to 24.9, overweight 25 to 29.9, and obese at 30 and above. Basal Metabolic Rate quantifies the minimum energy required to sustain life at rest. The Mifflin-St Jeor equation, published in 1990 and widely regarded as the most accurate for most adults, calculates BMR as (10 ร— weight in kg) + (6.25 ร— height in cm) โˆ’ (5 ร— age) ยฑ sex adjustment. The older Harris-Benedict equations, revised in 1984 by Roza and Shizgal, remain in common use. Total Daily Energy Expenditure is derived by multiplying BMR by a physical activity factor ranging from 1.2 for sedentary individuals to 1.9 for extremely active ones, following the methodology validated by doubly labeled water studies. Body fat percentage can be estimated without laboratory equipment using the U.S. Navy circumference method, which uses neck, waist, and hip measurements, or via BMI-derived equations adjusted for age and sex. The Jackson-Pollock skinfold method offers higher precision with calipers. Blood pressure classification, according to the American College of Cardiology and the 2017 ACC/AHA guidelines, defines normal as below 120/80 mmHg, elevated as 120 to 129 systolic, and hypertension stage 1 as 130 to 139 systolic or 80 to 89 diastolic. Target heart rate zones for aerobic exercise are derived from maximum heart rate estimates, most commonly using the formula 220 minus age in years, with moderate-intensity training typically defined as 50 to 70 percent of maximum heart rate and vigorous intensity at 70 to 85 percent, consistent with CDC and American Heart Association guidelines. These thresholds guide safe and effective cardiovascular conditioning.

History

The history behind the Progesterone to Estrogen Ratio Calculator traces back through the following developments. The history of health measurement stretches back to ancient Greece, where Hippocrates around 400 BCE laid the foundation for observational medicine by systematically recording patient symptoms, diet, and environment. His humoral theory, though scientifically superseded, established the principle that the body operates as an interconnected system subject to measurable imbalance. The transformation toward modern medicine accelerated in the 19th century. Louis Pasteur and Robert Koch developed germ theory in the 1860s and 1870s, identifying microorganisms as disease agents and enabling targeted interventions. Florence Nightingale, working during the Crimean War in the 1850s, introduced statistical analysis to nursing practice, demonstrating through data visualization that sanitation reduced mortality. Her work is foundational to evidence-based health measurement. The discovery of vitamins in the early 20th century, beginning with Casimir Funk's coinage of the term in 1912 and culminating in the isolation of vitamins A through K, created the field of nutritional science and gave rise to dietary reference intake frameworks. The World Health Organization, founded in 1948, subsequently established global standards for health metrics, disease classification through the International Classification of Diseases, and recommended daily allowances. The BMI as a clinical screening tool gained traction in the 1970s through Ancel Keys' large-scale epidemiological work, which validated Quetelet's index as a population-level obesity indicator. Through the 1980s and 1990s, the Framingham Heart Study produced landmark data linking cholesterol, blood pressure, and lifestyle factors to cardiovascular disease risk, directly shaping the numeric thresholds still used in health calculators. The evidence-based medicine movement, formalized by Gordon Guyatt and colleagues at McMaster University in the early 1990s, demanded that all health recommendations derive from systematically graded clinical evidence. The digital health era beginning in the 2000s brought these formulas to consumer devices, wearable sensors, and smartphone applications, expanding access to health self-monitoring on a global scale and enabling population-level data collection that continues to refine clinical reference ranges.

Share this calculator

Explore More

Frequently Asked Questions

The progesterone to estrogen ratio (Pg/E2 ratio) measures the relative balance between these two primary female sex hormones, which work in opposition to maintain reproductive health and hormonal homeostasis. This ratio is clinically significant because many symptoms attributed to hormone imbalance result not from absolute levels of either hormone alone but from their relative proportions. Estrogen dominance, where estrogen is relatively high compared to progesterone, has been associated with conditions including premenstrual syndrome, fibrocystic breasts, endometriosis, heavy menstrual bleeding, and increased risk of certain hormone-sensitive cancers. Monitoring this ratio helps clinicians evaluate ovulatory function, luteal phase adequacy, and the effectiveness of hormone replacement therapy.
The optimal Pg/E2 ratio varies significantly across the menstrual cycle because both hormones fluctuate dramatically throughout each phase. During the follicular phase (days 1-13), progesterone is very low (0.2-1.5 ng/mL) while estradiol rises gradually, producing a low ratio. At ovulation, estradiol peaks at 150-400 pg/mL while progesterone just begins to rise, creating the lowest ratio of the cycle. During the luteal phase (days 15-28), progesterone surges to 5-20 ng/mL while estradiol moderates to 40-200 pg/mL, producing the highest ratio. A clinical ratio (Pg ng/mL divided by E2 pg/mL times 1000) of 100-500 during the mid-luteal phase generally indicates adequate progesterone production and successful ovulation.
Estrogen dominance occurs when estrogen levels are disproportionately high relative to progesterone, even if absolute estrogen levels appear normal. Common causes include anovulatory cycles where no corpus luteum forms to produce progesterone, chronic stress which diverts progesterone precursors toward cortisol production, obesity (adipose tissue produces estrogen through aromatase activity), exposure to xenoestrogens in plastics and personal care products, and impaired estrogen metabolism in the liver. Symptoms may include heavy or irregular periods, breast tenderness, bloating, mood swings, weight gain (particularly around hips and thighs), headaches, decreased libido, and sleep disturbances. Treatment approaches include addressing root causes, supporting progesterone production, and optimizing estrogen detoxification pathways.
Converting between progesterone units requires knowing the molecular weight of progesterone, which is 314.46 g/mol. To convert from ng/mL to nmol/L, multiply by 3.18 (the conversion factor derived from 1000/314.46). To convert from nmol/L to ng/mL, divide by 3.18. For example, a progesterone level of 15 ng/mL equals approximately 47.7 nmol/L. Similarly, estradiol conversions use its molecular weight of 272.38 g/mol: multiply pg/mL by 3.671 to get pmol/L, or divide pmol/L by 3.671 to get pg/mL. These conversions are essential because laboratories in different countries use different unit systems, with ng/mL being common in the United States and nmol/L being standard in many European and Australian laboratories.
The timing of blood draws is critical for meaningful interpretation of the Pg/E2 ratio. For assessing luteal phase adequacy and ovulation confirmation, blood should be drawn 7 days after ovulation, which corresponds to approximately day 21 of a 28-day cycle. This is when progesterone reaches its peak concentration during the luteal phase. For women with irregular cycles, ovulation can be confirmed through basal body temperature tracking or urinary LH surge detection, with blood drawn 7 days after the confirmed ovulation day. Some clinicians recommend testing on multiple days (days 19, 21, and 23 for a 28-day cycle) to capture the progesterone peak. Fasting morning samples are preferred for consistency, as both hormones have mild diurnal variation.
During perimenopause (typically ages 40-55), the Pg/E2 ratio often decreases significantly because progesterone production declines more rapidly and earlier than estrogen. As ovulation becomes less frequent and less reliable, progesterone drops because it is primarily produced by the corpus luteum after ovulation. Meanwhile, estrogen levels may actually fluctuate wildly, sometimes spiking to very high levels before eventually declining. This creates a prolonged state of relative estrogen dominance that may explain many perimenopausal symptoms including heavy periods, breast tenderness, and mood changes. After menopause, both hormones reach very low levels, but the ratio becomes less clinically relevant. Hormone replacement therapy dosing aims to maintain a balanced ratio to minimize risks.
Educational Note: This calculator is provided for educational and informational purposes. Results are based on the formulas and inputs provided. Always verify important calculations independently. NovaCalculator processes calculator inputs client-side; optional analytics follow visitor consent settings.Reviewed by: NovaCalculator Medical Editorial Team โ€” Reviewed against WHO, NIH, and peer-reviewed clinical sources. Last reviewed: January 2026. ยฉ 2024โ€“2026 NovaCalculator.

Share this calculator

Formula

Pg/E2 Clinical Ratio = (Progesterone ng/mL / Estradiol pg/mL) x 1000

Where progesterone is measured in ng/mL (or converted from nmol/L by dividing by 3.18) and estradiol is measured in pg/mL (or converted from pmol/L by dividing by 3.671). The multiplication by 1000 normalizes the ratio for clinical interpretation. Optimal luteal phase ratio is typically 100-500.

Worked Examples

Example 1: Mid-Luteal Phase Assessment

Problem: A woman has a day 21 blood test showing progesterone of 15 ng/mL and estradiol of 150 pg/mL. Calculate the Pg/E2 ratio and assess luteal phase adequacy.

Solution: Clinical Ratio = (Progesterone ng/mL / Estradiol pg/mL) x 1000\nClinical Ratio = (15 / 150) x 1000 = 100\nSame-unit ratio (both in pg/mL): 15,000 / 150 = 100:1\nLuteal phase optimal range: 100-500\nProgesterone >10 ng/mL confirms ovulation\nResult: Ratio of 100 is at the lower end of normal luteal range

Result: Pg/E2 Ratio: 100 - Normal range, confirms ovulation with adequate luteal progesterone

Example 2: Suspected Estrogen Dominance

Problem: A woman with PMS symptoms has progesterone of 4 ng/mL and estradiol of 180 pg/mL on day 21. Evaluate the ratio.

Solution: Clinical Ratio = (4 / 180) x 1000 = 22.2\nSame-unit ratio: 4,000 / 180 = 22.2:1\nLuteal phase optimal range: 100-500\nRatio of 22.2 is well below the optimal range\nProgesterone of 4 ng/mL is below the 10 ng/mL threshold for confirmed ovulation\nThis suggests possible anovulation or luteal phase defect

Result: Pg/E2 Ratio: 22.2 - Estrogen Dominant. Low progesterone suggests anovulatory cycle or luteal phase deficiency

Frequently Asked Questions

What is the progesterone to estrogen ratio and why is it clinically important?

The progesterone to estrogen ratio (Pg/E2 ratio) measures the relative balance between these two primary female sex hormones, which work in opposition to maintain reproductive health and hormonal homeostasis. This ratio is clinically significant because many symptoms attributed to hormone imbalance result not from absolute levels of either hormone alone but from their relative proportions. Estrogen dominance, where estrogen is relatively high compared to progesterone, has been associated with conditions including premenstrual syndrome, fibrocystic breasts, endometriosis, heavy menstrual bleeding, and increased risk of certain hormone-sensitive cancers. Monitoring this ratio helps clinicians evaluate ovulatory function, luteal phase adequacy, and the effectiveness of hormone replacement therapy.

What are the normal progesterone to estrogen ratio ranges for different phases of the menstrual cycle?

The optimal Pg/E2 ratio varies significantly across the menstrual cycle because both hormones fluctuate dramatically throughout each phase. During the follicular phase (days 1-13), progesterone is very low (0.2-1.5 ng/mL) while estradiol rises gradually, producing a low ratio. At ovulation, estradiol peaks at 150-400 pg/mL while progesterone just begins to rise, creating the lowest ratio of the cycle. During the luteal phase (days 15-28), progesterone surges to 5-20 ng/mL while estradiol moderates to 40-200 pg/mL, producing the highest ratio. A clinical ratio (Pg ng/mL divided by E2 pg/mL times 1000) of 100-500 during the mid-luteal phase generally indicates adequate progesterone production and successful ovulation.

What causes estrogen dominance and what are its symptoms?

Estrogen dominance occurs when estrogen levels are disproportionately high relative to progesterone, even if absolute estrogen levels appear normal. Common causes include anovulatory cycles where no corpus luteum forms to produce progesterone, chronic stress which diverts progesterone precursors toward cortisol production, obesity (adipose tissue produces estrogen through aromatase activity), exposure to xenoestrogens in plastics and personal care products, and impaired estrogen metabolism in the liver. Symptoms may include heavy or irregular periods, breast tenderness, bloating, mood swings, weight gain (particularly around hips and thighs), headaches, decreased libido, and sleep disturbances. Treatment approaches include addressing root causes, supporting progesterone production, and optimizing estrogen detoxification pathways.

How do you convert progesterone between ng/mL and nmol/L units?

Converting between progesterone units requires knowing the molecular weight of progesterone, which is 314.46 g/mol. To convert from ng/mL to nmol/L, multiply by 3.18 (the conversion factor derived from 1000/314.46). To convert from nmol/L to ng/mL, divide by 3.18. For example, a progesterone level of 15 ng/mL equals approximately 47.7 nmol/L. Similarly, estradiol conversions use its molecular weight of 272.38 g/mol: multiply pg/mL by 3.671 to get pmol/L, or divide pmol/L by 3.671 to get pg/mL. These conversions are essential because laboratories in different countries use different unit systems, with ng/mL being common in the United States and nmol/L being standard in many European and Australian laboratories.

When should the progesterone to estrogen ratio be tested during the menstrual cycle?

The timing of blood draws is critical for meaningful interpretation of the Pg/E2 ratio. For assessing luteal phase adequacy and ovulation confirmation, blood should be drawn 7 days after ovulation, which corresponds to approximately day 21 of a 28-day cycle. This is when progesterone reaches its peak concentration during the luteal phase. For women with irregular cycles, ovulation can be confirmed through basal body temperature tracking or urinary LH surge detection, with blood drawn 7 days after the confirmed ovulation day. Some clinicians recommend testing on multiple days (days 19, 21, and 23 for a 28-day cycle) to capture the progesterone peak. Fasting morning samples are preferred for consistency, as both hormones have mild diurnal variation.

How does the progesterone to estrogen ratio change during perimenopause and menopause?

During perimenopause (typically ages 40-55), the Pg/E2 ratio often decreases significantly because progesterone production declines more rapidly and earlier than estrogen. As ovulation becomes less frequent and less reliable, progesterone drops because it is primarily produced by the corpus luteum after ovulation. Meanwhile, estrogen levels may actually fluctuate wildly, sometimes spiking to very high levels before eventually declining. This creates a prolonged state of relative estrogen dominance that may explain many perimenopausal symptoms including heavy periods, breast tenderness, and mood changes. After menopause, both hormones reach very low levels, but the ratio becomes less clinically relevant. Hormone replacement therapy dosing aims to maintain a balanced ratio to minimize risks.

References

Reviewed by Rahul Singh, Health & Wellness Specialist ยท Editorial policy